B-cell acute lymphoblastic leukemia
Drug research and approvals for B-cell acute lymphoblastic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 215 studies of B-cell acute lymphoblastic leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, and FDA has 2 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 215
- Trials authorized in Canada: 11
- FDA orphan approvals: 2
- EU medicines: 0
Recruiting Now
Newest start dates first, of 215 recruiting on ClinicalTrials.gov ↗- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic…NCT07758673 · Phase 1 · City of Hope Medical Center · starts Apr 17, 2027
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic LeukemiaNCT07854652 · Phase 1 · The First Affiliated Hospital of Soochow University · starts Dec 1, 2026
- Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory…NCT07572136 · Phase 1 · National Cancer Institute (NCI) · starts Nov 19, 2026
- A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide…NCT05621291 · Not applicable · National Cancer Institute (NCI) · starts Nov 19, 2026
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell…NCT07257419 · Phase 1 · St. Jude Children's Research Hospital · starts Oct 3, 2026
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With…NCT07648264 · Phase 3 · CSL Behring · starts Sep 15, 2026
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in…NCT07020533 · Phase 1 · City of Hope Medical Center · starts Sep 9, 2026
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)NCT07476729 · Phase 3 · Charite University, Berlin, Germany · starts Sep 1, 2026
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
Trials Authorized in Canada
The 10 newest of 11; search them all in Canada trials| May 28, 2026 | Open label dose-escalation and dose expansion study to evaluate the safety, expansion, persistence and clinical activity of ucart22 {allogeneic engineered…UCART22 / CLLS52 | CELLECTIS S.A. | Closed |
| Apr 15, 2026 | A phase 2/3, randomized, open-label, comparison study of mk-1045 versus blinatumomab in participants with relapsed or refractory cd 19+ b-cell acute…MK-1045 | Merck & Co. (MSD) | Ongoing |
| Dec 23, 2025 | Phase II study of subcutaneous blinatumomab plus ponatinib for bcr-abl positive b-cell acute lymphoblastic leukemiaBLINCYTO / ICLUSIG | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA | Pending |
| Nov 27, 2025 | A phase 3, open-label, randomized, controlled trial of subcutaneous versus intravenous blinatumomab in newly diagnosed adults with philadelphia chromosome…SUBCUTANEOUS (SC) BLINATUMOMAB / RITUXIMAB | Amgen | Pending |
| Sep 5, 2025 | A phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of administration of subcutaneous (sc) blinatumomab in pediatric participants with…BLINCYTO | Amgen | Pending |
| Aug 14, 2025 | An international pilot study of chemotherapy and tyrosine kinase inhibitors with blinatumomab in patients with newly-diognosed philadelphia chromosome-positive…BLINCYTO | CHILDRENS ONCOLOGY GROUP | Ongoing |
| Jun 10, 2022 | A phase 1/2 open-label study to investigate the safety, efficacy, and pharmacokinetics of administration of subcutaneous blinatumomab for the treatment of…BLINATUMOMAB (SC) | Amgen | Ongoing |
| Feb 11, 2021 | A phase II pilot trial to estimate survuval after a non-total body irradiation (tbi) based conditioning regimen in patients diagnosed with b-acute…THIOTEPA | PEDIATRIC TRANSPLANTATION AND CELLULAR THERAPY CONSORTIUM | Closed |
| Feb 5, 2021 | A phase 2 study of blinatumomab (nsc# 765986, ind# 125462) in combination with nivolumab (nsc # 748726, ind# 125462), a checkpoint inhibitor of pd-1, in b-all…BLINCYTO / OPDIVO | CHILDRENS ONCOLOGY GROUP | Ongoing |
| Apr 10, 2019 | A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti-cd22 monoclonal antibody) to frontline therapy in young…INOTUZUMAB OZOGAMICIN / RITUXAN | CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Mar 6, 2024 | Besponsatreatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1… | Wyeth Pharmaceuticals, LLC | Approved |
| Aug 17, 2017 | inotuzumab ozogamicinTreatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) | Wyeth Pharmaceuticals, LLC | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA